Nationwide Outcomes of Advanced Melanoma According to BRAF(V600) Status

J. van Breeschoten, M.W.J.M. Wouters, L.C. de Wreede, D.H. Hilarius, J.B. Haanen, C.U. Blank, M.J.B. Aarts, F.W.P.J. van den Berkmortel, J.W.B. de Groot, G.A.P. Hospers, E. Kapiteijn, D. Piersma, R.S. van Rijn, K.P.M. Suijkerbuijk, W.A.M. Blokx, A.J. ten Tije, A.A.M. van der Veldt, G. Vreugdenhil, M.J. Boers, A.J.M. van den Eertwegh

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Web of Science)
Original languageEnglish
Pages (from-to)82-89
Number of pages8
JournalAmerican Journal of Clinical Oncology-Cancer Clinical Trials
Volume44
Issue number2
DOIs
Publication statusPublished - 1 Feb 2021

Keywords

  • advanced melanoma
  • anti-pd-1-ligands
  • braf
  • braf mutation
  • checkpoint inhibitors
  • ctla-4 inhibitor
  • mek inhibitors
  • national registry
  • MEK inhibitors
  • BRAF
  • anti-PD-1-ligands
  • BRAF mutation
  • CTLA-4 inhibitor
  • National Registry

Cite this